Special Issue "Enzymatic Inhibitors from Natural Sources: A Huge Collection of New Potential Drugs 2022"
Deadline for manuscript submissions: closed (20 November 2022) | Viewed by 2203
Interests: drug discovery; type 2 diabetes; insulin resistance; protein tyrosine phosphatase; cancer cell metabolism; chemoresistance; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Interests: n vitro and ex vivo, of anti-diabetical properties of natural compounds and the evaluation of novel drugs; eco-toxicological impact of novel pollutants
The natural world is undoubtedly the largest collection of molecules with medical properties known by humankind. This is confirmed by the fact that every year, hundreds of new natural inhibitors are derived from the natural world and able to target important biological human proteins or enzymes are identified and characterized. In the last decades, some of these molecules have been considered promising therapeutic molecules because of their high selectivity or potency and have been included in clinical trials to evaluate their effectiveness.
This Special Issue aims to highlight the properties of natural inhibitors and the advantages that could be obtained from their use as drugs for the treatment of human diseases, including cancer, neurodegenerative diseases, diabetes, chronic inflammation, bacterial infections and obesity. We encourage all researchers interested in this topic to present research articles or reviews concerning natural compounds that act as inhibitors of specific biological targets. This Special Issue can include structure–activity relationship studies, analyses of the mechanisms of action of these inhibitors, crystallographic analyses of target–inhibitor complexes and studies about specificity, bioavailability, toxicity and effectiveness of new inhibitors both in vitro and in vivo, as well as results of clinical trials carried out to evaluate the effectiveness of natural inhibitors in humans.
Prof. Paolo Paoli
Dr. Massimo Genovese
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Natural molecules
- Inhibition mechanism
- Target therapy
- Ligand affinity
- Docking in silico
- Targeted therapy